Subscribe

Shawn Bliss, MSN, ARNP, AOCN

Florida Cancer Specialists

Authored Items

Abiraterone Acetate: Expanded Indication for Metastatic Prostate Cancer
By Shawn Bliss, MSN, ARNP, AOCN
TON - May 2013, Vol 6, No 4
Genitourinary Cancers
Abiraterone acetate is a novel antiandrogen agent that has recently received an expanded indication for treatment in men with metastatic castration-resistant prostate cancer (mCRPC).

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, monthly TON print publication and TON weekly e‑newsletter.

Subscribe
© Amplity Health. All Rights Reserved. Privacy Policy.